Imugene Ltd (IMU.AX) announced that it entered into a co-development partnership with JW Therapeutics (Shanghai) Co., Ltd (2126.HK), a leading biotechnology firm specializing in cell-based immunotherapies. The collaboration will evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) with JW's Carteyva, a CD19-directed autologous CAR-T cell therapy, for patients with advanced solid tumors.
The program will begin with preclinical in vitro and in vivo studies, followed by a Phase 1 investigator-initiated trial conducted exclusively in China at premier CAR-T clinical centers. This novel approach leverages Imugene's CF33-CD19 virus to induce CD19 expression on tumor cells, making them vulnerable to CD19 CAR-T therapies — a groundbreaking "mark and kill" strategy designed to expand CAR-T's reach into solid tumors.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.